Girardi P1, Rapinesi C, Chiarotti F, Kotzalidis GD, Piacentino D, Serata D, Del Casale A, Scatena P, Mascioli F, Raccah RN, Brugnoli R, Digiacomantonio V,Ferri VR, Ferracuti S, Zangen A, Angeletti G. ...Read More
This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Levkovitz, Y., Sheer, A., Harel, E. V., Katz, L. N., Most, D., Zangen, A., & Isserles, M. (2011). Brain stimulation, 4(4), 266-274.
This study examined the effect of the Brainsway® Deep TMS (Transcranial Magnetic Stimulation) H-coil stimulation on depressed patients, and evaluated separately the effect on depressive symptoms and on one of depression’s core symptoms – apathy. In the study, antidepressant medication treatment was ceased, and Deep Transcranial Magnetic stimulation was given 5 days a week, over 4 weeks. The study demonstrated that brain stimulation using the Deep TMS H-coil significantly alleviates depressive symptoms including apathy, but only if pre-treatment apathy was not very severe.